// App-Quantinova.ai

POS0070 (2022) : CONTINUED TREATMENT WITH NINTEDANIB IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (lcSSc) AND INTERSTITIAL LUNG DISEASE (ILD)

Researchers

Presenter

  • Y. Allanore

Principal Investigators

  • D. Khanna

  • V. Smith

  • M. Aringer

  • A. M. Hoffmann-Vold

  • M. Kuwana

  • P. A. Merkel

  • A. James

  • S. Sambevski

  • M. Alves

  • C. P. Denton

Medical Centers

  • , Descartes University, APHP, Cochin Hospital, Department of Rheumatology A, Paris, Italy

  • University of Michigan School of Medicine, Ann Arbor, United States of America

  • Ghent University Hospital, Department of Rheumatology and Internal Medicine, Ghent, Belgium

  • University Medical Center & Faculty of Medicine Carl Gustav Carus, Technical University of Dresden, Division of Rheumatology, Department of Medicine III, Dresden, Germany

  • Oslo University Hospital, Department of Pathology, Oslo, Norway

  • Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Tokyo, Japan

  • University of Pennsylvania, Division of Rheumatology, Department of Medicine, Philadelphia, United States of America

  • Elderbrook Solutions GmbH, Statistics, Bietigheim-Bissingen, Germany

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom

Locations

  • France

  • United States

  • Belgium

  • Germany

  • Norway

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved